|Articles|March 1, 2018
- Pharmaceutical Executive-03-01-2018
- Volume 38
- Issue 3
Pharmaceutical Executive, March 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 8 years ago
Pharma: Meet Your New Neighborsalmost 8 years ago
Risk Sharing, Italian Styleabout 8 years ago
The Quest to Measure Upabout 8 years ago
Full Disclosure Demanded for Pharma Industryabout 8 years ago
Setting the Standard: William Soliman, ACMAabout 8 years ago
The Law of Unintended Consequencesabout 8 years ago
Pricing Turning Point: The Case for Innovating Pharma’s Modelabout 8 years ago
Showdown Nears on Europe Research Incentivesabout 8 years ago
The Personalized Genetic Profile: It’s Time to Alignabout 8 years ago
Country Report: IndiaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
What is Shadow AI and How is it Impacting Pharma Companies?
3
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
4
Agentic AI and the Future of Commercial Excellence in Life Sciences
5